High-Risk IPO: Gritstone Oncology

High-Risk IPO: Gritstone Oncology

Gritstone Oncology focuses on cancer drugs—presently in pre-clinical trials. This focus is an extremely risky proposition, given the effort, cost, length of time and complexity that lies ahead as they move toward clinical trials. Read Seeking Alpha’s Donovan Jones for...

Pin It on Pinterest